Support that never stops

Inspired
innovation

Support that never stops

Support that
never stops

Trusted outcomes

Trusted
outcomes

Bladder and bowel control by the numbers

Overactive bladder

Nearly

43

million people in the U.S. experience symptoms
of OAB.1-3

Fecal incontinence

More than

21

million people in the U.S. experience symptoms
of FI.2,4,5

OAB and FI

An estimated

13

million people in the U.S. experience both.1-3,6

The time is now for bladder and bowel control.

Inspired innovation

Because life is measured in moments.

The most extensive neuromodulation portfolio for bladder and bowel control.

Giving you and your patients more choices

Implantable tibial neuromodulation

For patients with UUI
Support that never stops

Altaviva™ system

A simple experience

  • Single,7 minimally invasive procedure8
  • No sedation or imaging required7
  • Expected 15 years of battery life†,9
  •  

Sacral neuromodulation

For patients with OAB, NOUR, & FI
Support that never stops

InterStim™ X system

Proven technology, durable outcomes10-12

  • Basic evaluation leads designed to minimize migration13,14
  • Expected up to 10 years of battery life‡, and at low energy settings, up to 15 years§

Percutaneous tibial neuromodulation

For patients with OAB
Support that never stops

NURO™ system

Quick, in-office therapy

  • Easy therapy delivery
  • 30-minute therapy sessions
  • 12 weekly sessions, then monthly maintenance sessions

† Based on clinical and bench testing for expected therapy settings
‡ Under expected therapy settings and telemetry use
§Please see System Eligibility, Battery Longevity, Specifications manual for battery longevity estimates

From originator to innovator

The same passion that inspired us to originate neuromodulation for bladder and bowel control drives our innovation today.

Broad MRI compatibility
Unparalleled expertise. Unmatched access.

  • Altaviva™ system — Full-body⋄ MRI ready from the start7
  • InterStim™ system — Full-body⋄ 1.5T and 3T MRI compatible
    • Only InterStim™ systems provide MRI access without impedance disqualifiers15,16

⋄ Under certain conditions; see approved labeling for details.

Exclusive Medtronic battery technology
Powered by ~70 years of expertise

From pacemakers to neurostimulators — our Altaviva™ and InterStim™ device batteries offer the same reliability as our life-changing pacemakers

Engineered not outsourced.

Digital Health Solution

MyFuture™ digital app

Education | Tracking | Reporting

  • Voiding diary collection and review
  • Personalized patient education
  • Physician portal designed to streamline your experience

Support that never stops

Because every moment in care matters.

Comprehensive, end-to-end support across the care continuum

Support icon
Full patient journey and device support
  • In-house prior authorization support
  • Support Link™ outreach to InterStim™ patients
  • Post-implant device education calls
  • 24/7 MRI technical support
Support icon
Robust clinician training, education, and support
  • Digital, on-demand and in-person education
  • Fellow and resident education programs
  • Advanced practice provider education
  • Seasoned health economic managers
 
Support icon
Patient-centered awareness, education, and support
  • Physician finder
  • Therapy awareness partnerships
  • Patient ambassador program
  • MyFuture™ app symptom tracking, education and support

Trusted outcomes

Because freedom is the most powerful outcome.

Backed by 30 years of clinical data for urinary control conditions17 and 20 years of clinical data for bowel control.18

Fran’s Altaviva™ system story

Road trips. International travel. Cruises.

Not having to let my bladder control me lets me go out more… do more things. It’s just the freedom.”

— Fran, Altaviva™ system patient

Individual results may vary.
This patient participated in the TITAN 2 clinical trial that studied the investigational tibial neuromodulation device and its use. For more information, visit clinicaltrials.gov: NCT05226286.

Morgon’s InterStim™ system story

Adventure. Time with loved ones.

InterStim™ has helped me feel better about my life… it continues to allow me to do the things I know I wouldn’t be able to do without it.”

— Morgon, InterStim™ system patient

Individual results may vary.

For stimulation devices, common risks may include surgical infection, pain, undesirable changes in urinary or bowel function, and uncomfortable stimulation. Refer to Important Safety Information for more details.

Time-tested results that change lives

#1 Sacral neuromodulation device choice globally for OAB and FI patients19

years of innovation

clinical publications

patients treated with InterStim™ systems

References

  1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336.
  2. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data, 2024. https://www.cdc.gov/nchs/nhanes/Default.aspx. Accessed January 31, 2025.
  3. US Census Bureau 2020. US adult and under-age-18 populations: 2020 census. https://www.census.gov/library/visualizations/interactive/adult-and-under-the-age-of-18-populations-2020-census.html. Accessed January 31, 2025.
  4. Whitehead WE, Borrud L, Goode PS, et al. Fecal Incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137(2):512-517.
  5. Ditah I, Devaki P, Luma HN et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010. Clin Gastroenterol Hepatol. 2014;12:636-643.
  6. Coyne KS, et al. The prevalence of chronic constipation and fecal incontinence among men and women with symptoms of overactive bladder. BJU Int. 2011 Jan;107(2):254-61.
  7. M028930C001RevC - Altaviva™ Model P7850N Neurostimulator Implant Manual.
  8. Cameron AP, Chung DE, Dielubanza EJ et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder (2024). J Urol. 2024;212:11-20. 
  9. M028929C001RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N.
  10. Siegel S, Noblett K, Mangel J, et al. Five-year follow-up results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol. 2018;199(1):229-236.
  11. Medtronic InterStim™ Clinical Summary 2018.
  12. Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.
  13. NDHF1534-200202, Marketing claim data summary: Axonics vs Medtronic Basic Evaluation Lead, October 2020. Medtronic data on file.
  14. Elterman D, Michaels J, Margolis E, et al. Prospective, multicenter study to evaluate performance and safety of a re‐engineered temporary lead for InterStim™ therapy evaluation. Neurourol Urodyn. 2022;1-8.
  15. Medtronic MRI Guidelines for InterStim™ systems, M980291A032 Rev A.
  16. Axonics™ MRI guidelines, US, 110-0092-001rAM. Updated February 2024.
  17. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352-357.
  18. National Library of Medicine. National Institutes of Health (NIH). NCT00200005: Sacral nerve stimulation for anal incontinence and bowel control (MDT-301).  https://clinicaltrials.gov/study/NCT00200005. Accessed February 12, 2026.
  19. Mordor Intelligence: Sacral Nerve Stimulation Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031). https://www.mordorintelligence.com/industry-reports/sacral-nerve-stimulation-market. Accessed February 12, 2026.